Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21(WAF1/CIP1) because of estrogen-mediated inhibition of nascent p21(WAF1/CIP1). Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21(WAF1/CIP1) gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21(WAF1/CIP1) and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Estrogen receptor activation promotes cell proliferation in estrogen‐responsive tissues (breast and endometrium) [435].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [435]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Connections and Regulation of the Human Estrogen Receptor
McDonnell, D. P., & Norris, J. D. (2002) · Science · doi:10.1126/science.1071884 · Cited by 579
The myc Oncogene: arvelouslomplex
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84004-0 · Cited by 463
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
Self-citationOpposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3
Gartel, A. L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., & Tyner, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081074898 · Cited by 417
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science's STKE · doi:10.1126/stke.2002.138.re9 · Cited by 369
Research works printed but not linked: 1
- Lai A, Sarcevic B, Prall OW & Sutherland RL 2001 Insulin/IGF-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21 WAF1/Cip1 . Journal of Biological Chemistry 276 25823-25833.
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235
“Most importantly, the overall functional ‘‘landscape’’ fits with the known role of estrogen hormones as activators of cell proliferation [34].”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citationEstrogen–gut microbiome axis: Physiological and clinical implications
Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.025 · Cited by 993
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Metadata
- Authors
- Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, R L
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 2
- Pages
- 179-186
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2121155074
- Cited by
- 333
- References
- 53
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 12 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 9 · 2016: 15 · 2015: 13 · 2014: 17 · 2013: 7 · 2012: 9
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Cancer Council NSW
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen, antiestrogens, breast cancer, cell cycle progression, c-Myc, cyclin D1, p21, cyclin E/CDK2, G1/S phase, MCF-7 cells, quiescence, carcinogenesis, cyclin-dependent kinase inhibitors
- MeSH terms
- Animals, Breast Neoplasms, Cell Cycle, Estrogens, Female, Humans, Cyclins, Proto-Oncogene Proteins c-myc, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin E, Cyclin D1, Estrogen Receptor Modulators, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.